Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study.

[1]  H. Tournaye,et al.  Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. , 2006, Human reproduction.

[2]  K. Lukaszuk,et al.  Optimization of estradiol supplementation during the luteal phase improves the pregnancy rate in women undergoing in vitro fertilization-embryo transfer cycles. , 2005, Fertility and sterility.

[3]  D. Carone,et al.  A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years. , 2004, Fertility and sterility.

[4]  D. Shapiro.  An overview of GnRH antagonists in infertility treatments. Introduction. , 2003, Fertility and sterility.

[5]  A. Atwood,et al.  Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. , 2002, Human reproduction.

[6]  O. Ortmann,et al.  Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells. , 2001, European journal of endocrinology.

[7]  M. Eijkemans,et al.  Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon). , 2001, Fertility and sterility.

[8]  A. Weissman,et al.  Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles. , 2000, Fertility and sterility.

[9]  R. Frydman,et al.  Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). , 2000, Fertility and sterility.

[10]  S. Pavlou,et al.  Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells. , 1995, American journal of obstetrics and gynecology.

[11]  D. Klingmüller,et al.  Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. , 1994, Human reproduction.

[12]  E. Loumaye.  The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. , 1990, Human reproduction.

[13]  D Jordan,et al.  GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. , 1989, Endocrinology.

[14]  N. Laufer,et al.  The pattern of luteal phase plasma progesterone and estradiol in fertile cycles. , 1982, American journal of obstetrics and gynecology.

[15]  J. Engel,et al.  GnRH agonists and antagonists in assisted reproduction: pregnancy rate. , 2006, Reproductive biomedicine online.

[16]  P. Devroey,et al.  Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles. , 2006, Reproductive biomedicine online.

[17]  E. Kolibianakis,et al.  Direct ovarian effects and safety aspects of GnRH agonists and antagonists. , 2002, Reproductive biomedicine online.